MISSISSAUGA, Ontario, June 16, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ)
("Aralez" or the "Company"), today announced the results of the matters voted upon at the Company's 2016 annual general meeting
(the "Meeting") of shareholders (the "Shareholders") held earlier today, which included the election of directors, as described
below.
The total number of common shares of the Company ("Common Shares") represented by Shareholders present in person or represented
by proxy at the Meeting was an aggregate of 49,371,169, representing 77.12% of the Company's issued and outstanding Common
Shares.
According to proxies received and a vote by ballot, the voting results in respect of each of the following eight director
nominees, all of whom previously served as directors of the Company, were as follows:
|
Nominee
|
Number of Shares
|
Percentage of Votes Cast
(approximate)
|
|
Votes For:
|
Votes
Withheld:
|
Votes For:
|
Votes
Withheld:
|
|
Arthur S. Kirsch (Chairman)
|
36,864,255
|
701,174
|
98.13%
|
1.87%
|
|
Adrian Adams
|
36,924,816
|
640,613
|
98.29%
|
1.71%
|
|
Jason M. Aryeh
|
34,724,222
|
2,841,207
|
92.44%
|
7.56%
|
|
Neal F. Fowler
|
34,912,811
|
2,652,618
|
92.94%
|
7.06%
|
|
Rob Harris
|
36,728,124
|
837,305
|
97.77%
|
2.23%
|
|
Kenneth B. Lee, Jr.
|
34,432,470
|
3,132,959
|
91.66%
|
8.34%
|
|
Seth A. Rudnick, M.D.
|
34,916,599
|
2,648,830
|
92.95%
|
7.05%
|
|
F. Martin Thrasher
|
37,299,273
|
266,156
|
99.29%
|
0.71%
|
Each of the other matters put forward before Shareholders for consideration and approval at the Meeting, as described in the
Company's proxy statement dated May 6, 2016, was duly approved by the requisite number of votes.
Final voting results of all other matters voted on at the Meeting will be made available on EDGAR at www.sec.gov and SEDAR at www.sedar.com.
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering
meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing
products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is planned to be in Princeton, NJ and
the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at
www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact:
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aralez-announces-voting-results-from-2016-annual-general-meeting-of-shareholders-300286334.html
SOURCE Aralez Pharmaceuticals Inc.
